


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT

**F-STAR ENTERED INTO STRATEGIC COLLABORATION AND LICENCE
AGREEMENT WITH TAKEDA TO DISCOVER AND DEVELOP NEXT-GENERATION
MULTI-SPECIFIC ANTIBODIES**

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**” or “**Sino Biopharm**”) announces that F-star Therapeutics, Inc. (“**F-star**”), a group company of Sino Biopharm, has entered into a strategic discovery collaboration and licence agreement with Takeda. The collaboration will leverage F-star’s proprietary fully-human Fcab™ and tetravalent mAb²™ platforms to research and develop next-generation multi-specific immunotherapies for patients with cancer.

Under the terms of the agreement, F-star and Takeda will jointly research and develop novel Fcab domains against undisclosed immuno-oncology targets. Takeda will receive a worldwide, exclusive royalty-bearing licence to research, develop, and commercialise antibodies incorporating Fcab domains arising from the collaboration, and F-star will retain the right to research, develop, and commercialise antibodies incorporating certain other Fcab domains.

F-star will receive an undisclosed upfront payment as well as research funding for the period of the collaboration. F-star is also eligible to receive potential future development and commercialisation milestone payments of up to approximately US\$1 billion if all milestones across multiple programs are reached during the term of the agreement, plus royalties on potential annual net sales of any commercial product resulting from the licence.

This collaboration and licence agreement represents the third licence agreement that F-star and Takeda have established. Licence agreements for a first and second immune-oncology bispecific antibody were announced in July 2022 and March 2023, respectively.

Entering into this collaboration and licence agreement further expands the Group's relationship with Takeda which shares the Group's vision of developing pioneering multi-specific immunotherapies so more people with cancer can live longer with improved lives. This strategic collaboration leverages the capabilities of both companies by combining F-star's clinically validated Fcab™ and mAb²™ platforms with Takeda's unique understanding of the immune system and its ability to progress drugs to the clinic.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 5 July 2023

As at the date of this announcement, the Board of the Company comprises seven executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Tian Zhoushan and Ms. Li Mingqin and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.